A novel treatment strategy by natural products in NLRP3 inflammasome‐mediated neuroinflammation in Alzheimer’s and Parkinson’s disease

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common neuro-degenerative diseases. Many studies have demonstrated that the release of NLRP3 inflammasome-mediated proinflammatory cytokines by the excessive activation of microglia is associated with the pathogenesis of AD and PD and suggested that the NLRP3 inflammasome plays an important role in AD and PD development. In both diseases, various stimuli, such as Aβ and α‐synuclein, acceler-ate the formation of the NLRP3 inflammasome in microglia and induce pyroptosis through the expression of interleukin (IL)‐1β, caspase‐1, etc., where neuroinflammation contributes to gradual progression and deterioration. However, despite intensive research, the exact function and regulation of the NLRP3 inflammasome has not yet been clearly identified. Moreover, there have not yet been any experiments of clinical use, although many studies have recently been conducted to improve treatment of inflammatory diseases using various inhibitors for NLRP3 inflammasome pathways. However, recent studies have reported that various natural products show improvement effects in the in vivo models of AD and PD through the regulation of NLRP3 inflammasome assembly. There-fore, the present review provides an overview of natural extraction studies aimed at the prevention or treatment of NLRP3 inflammasome‐mediated neurological disorders. It is suggested that the discovery and development of these various natural products could be a potential strategy for NLRP3 inflammasome‐mediated AD and PD treatment.